A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.

被引：1
|
作者：
Townsend, Amanda Rose
Hardingham, Jennifer
Tebbutt, Niall C.
Karapetis, Christos Stelios
Singhal, Nimit
Joshi, Rohit
Yeend, Sue
Cooper, Pamela
Dorward, Hilary
Price, Timothy Jay
机构：
[1] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Heidelberg Repatriat Hosp, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Australia
[3] Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA, Australia
[4] Flinders Univ S Australia, Flinders Ctr Innovat Canc, Adelaide, SA, Australia
[5] Royal Adelaide Hosp, Adelaide, SA, Australia
[6] Univ Adelaide, Lyell McEwin Hosp, Adelaide, SA, Australia
[7] Queen Elizabeth Hosp, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.643
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
643
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Townsend, A.
    Tebbutt, N.
    Karapetis, C.
    Cooper, P.
    Singhal, N.
    Yeend, S.
    Pirc, L.
    Joshi, R.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).
    Townsend, Amanda Rose
    Pirc, Louise
    Cooper, Pamela
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
    Townsend, A. R.
    Pirc, L.
    Hardingham, J.
    Karapetis, C. S.
    Tebbutt, N. C.
    Singhal, N.
    Price, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
    Townsend, Amanda
    Tebbutt, Niall
    Karapetis, Christos
    Cooper, Pamela
    Singhal, Nimit
    Yeend, Susan
    Pirc, Louise
    Joshi, Rohit
    Hardingham, Jennifer
    Price, Timothy
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3838 - 3844
  • [5] A phase 1B study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Price, T. J.
    Pirc, L.
    Cooper, P.
    Tebbutt, N.
    Karapetis, C.
    Singhai, N.
    Townsend, A. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S549 - S549
  • [6] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)
    Sharma, S.
    Reid, T.
    Hoosen, S.
    Garrett, C.
    Beck, J.
    Davidson, S.
    MacKenzie, M.
    Brandt, U.
    Hecht, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Reid, Tony R.
    Garrett, Christopher R.
    Beck, J. Thaddeus
    Davidson, Sheldon J.
    Mackenzie, Mary J.
    Brandt, Ulrike
    Rizvi, Syed
    Sharma, Sunil
    ANTICANCER RESEARCH, 2015, 35 (03) : 1567 - 1573
  • [9] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
12345